Search
When Time Matters, Clarity Leads...

We are
Medmira

We are an innovation-driven company on a mission to transform healthcare through rapid testing that save time, reduce costs empower decisions, and improve lives.

Our technologies deliver the accuracy clinicians trust and the speed patients need, turning critical moments into confident action.

From frontline care to global health initiatives, we combine rigorous science, certified manufacturing, and relentless innovation to create solutions that answer tomorrow’s needs.

Our Vision

To lead the future of rapid diagnostics with fast, accurate, and accessible testing solutions that strengthen global health and create lasting value for our partners.

Our Mission

To advance our proprietary technology platforms to develop and manufacture high-performance, easy-to-use, and cost-efficient diagnostic products that support better clinical decisions and help protect human health worldwide.

innovation
Our Values: What we stand for...

Guided by Research Driven by Innovation

Research and development empower us to transform rapid testing into smarter, more practical solutions. We identify new biomarkers to deepen insight into disease dynamics, advance point-of-care testing to deliver laboratory-level accuracy, and apply AI through our upcoming MiROQ system to evaluate disease severity, duration, and progression with consistent, data-driven precision – supported by a versatile portfolio and robust technology that enable rapid adaptation to evolving requirements.

tubes

Committed to 
Quality

Quality is at the core of who we are. We design and manufacture our products within a robust and continuously improving quality management system that meets internationally recognized standards and supports the needs of our partners worldwide.

medmira partners

Partner for Progress

We collaborate with partners to advance our solutions and expand access to reliable rapid testing, aligning expertise across development, distribution, and real-world implementation. Shared data, market insights, and operational feedback enable us to adapt quickly to regional needs and evolving requirements, strengthening both performance and availability. Through strong collaboration, we ensure that high-quality testing reaches the settings where it creates measurable value.

integrity

Act with Integrity

We uphold transparency and accountability across the full lifecycle of our solutions. Our products are developed and validated through rigorous clinical studies and performance evaluations that meet recognised scientific and regulatory standards. By adhering to established approval pathways and maintaining clear communication of test performance, we ensure that healthcare professionals and partners can depend on the accuracy, safety, and consistency of our solutions.

Awards & Institutional Recognition

Our Story

Founded in 1993 in Halifax, MedMira has grown from a Canadian diagnostics pioneer into an internationally active provider, supported by regulatory milestones, continued innovation, and global partnerships. In recent years, the company has advanced its pipeline through sustained internal investment, with new products approaching market readiness.

2025
  • Health Canada approval for Reveal® G4 HIV rapid test
  • Health Canada approval for Reveal® TP rapid test
  • Completion of first phase of clinical trials for Multiplo® TP/nTP in Canada
2024
  • Canada patent for MiROQ - MedMira’s quantitative test system
  • Grant from CIHR for clinical trials in Canada for Multiplo® TP/nTP rapid test
  • Health Canada approval for Multiplo® TP/HIV rapid test
  • Grant from CIHR for clinical trials in Canada for Multiplo® TP/HIV self-test
2023
  • CE mark for VYRA (SARS-CoV-2 and Flu A and B) antigen rapid test
  • US FDA approval for MedMira’s advanced G4 HIV-1/2 rapid test
2022
  • CE mark for VYRA (SARS-CoV-2) antigen rapid test
  • CE mark for Multiplo® TP/nTP rapid test
  • US patent for MiROQ - MedMira’s quantitative test system
  • Grant from Johns Hopkins for multiple STI Saliva rapid test
  • Grant from CIHR for clinical trials in Canada for Reveal® TP rapid test
  • Queen Elizabeth II’s Platinum Jubilee Medal for contributions during the pandemic
2021
  • Development of VYRA SARS-CoV-2, Flu A, Flu B and RSV (4 in 1) antigen rapid test
2020
  • First Total antibody Rapid Test for SARS-COV-2
  • Development of VYRA SARS-CoV-2 antigen test
2016
  • CE mark on TP/HIV rapid test, confirming EU compliance
2015
  • US FDA approval G4 HIV-1 finger stick rapid test
2014
  • Development of Multiplo® HBV/HIV/HCV rapid test
  • Outstanding Business Innovation Award Canada, Hong Kong Canada Business Achievement Award
2012
  • $4.2 million US Army contract for multiplex HIV and Hepatitis B/C rapid test
  • Canadian Manufacturer’s & Export New Technology Award
  • Royal Society of Medicine Medical Innovations Summit - Keynote speaker
  • United Nations Conference on Trade and Development XIII - Keynote Speaker
2011
  • $2.3 million US Army contract for new rapid Hepatitis B test
2008
  • US and China patents on RVF
  • Tech Awards Laureate of the Tech Museum of Innovation
2007
  • European patent on RVF Technology
  • The Economist Innovation Award: Bioscience
2006
  • CE mark on rapid HIV test
2003
  • Rapid HIV test approved by China CFDA and U.S. FDA
2000
  • Went public and listed our stock on the TSXV under the symbol MIR
1998
  • Rapid HIV test approved by Health Canada
1993
  • Company founded
  • In 1993, co-founders Hermes Chan and Carlina Hui, both Acadia University graduates, brought RVF Technology™ to life - a MEDical MIRAcle that became MedMira, enabling instant antibody detection across targets.
Committed to quality
Certified & Proven Quality

Our quality management system is ISO 13485:2016 certified, compliant with the United States Food and Drug Administration’s current Good Manufacturing Practices (cGMP: Quality System Regulation Part 820 of CFR Title 21, Volume 8), European Union’s Directive 98/79/EC on in vitro diagnostic medical devices, and Health Canada Medical Device Regulations (SOR/98-282).

Additionally, we adhere to ISO 14971 (Application of Risk Management to Medical Devices) and ISO 2859 (Sampling Procedures for Inspection by Attributes). Certification and compliance to these requirements attests to our ability to maintain the highest standard of quality in medical device manufacturing, product development and corporate conduct.

Our products have been approved by regulators and UN agencies worldwide.

FDA

Health Canada

International Trade Centre (ITC)

Pan American Healtch Organization (PAHO)

UN Development Programme (UNDP)

UN Office for Project Services (UNOPS)

UN Office at Vienna (UNOV)

UN Population Fund (UNFPA)

United States Agency for International Development (USAID)

Privacy Policy

Last updated: April 20, 2026

MedMira Inc. (“MedMira”, “we”, “us”, or “our”) is committed to protecting personal information in accordance with applicable privacy laws, including the Personal Information Protection and Electronic Documents Act (PIPEDA) in Canada, as well as applicable United States and international privacy requirements.

This Privacy Policy describes how we collect, use, disclose, and safeguard personal information through our website. Our website is primarily informational in nature and does not provide user accounts, applications, or diagnostic services.

Terms And Conditions Of Use

Please Read These Terms Carefully Before Using This Site. This website is provided by MedMira Inc. (MedMira) and may be used for informational purposes only. By using the site or downloading materials from the site, you agree to abide by the terms and conditions set forth in this notice. If you do not agree to abide by these terms and conditions do not use the site or download materials from the site.

Subscribe
Join our newsletter

Receive company updates, regulatory milestones, and event announcements.

By subscribing, you agree to our Privacy Policy and consent to receive updates.

CFO & Head of Commercialization

Markus Meile

Markus joined MedMira in 2010, and moved into the role of Chief Financial Officer in 2014.

He previously served on the Company’s Board of Directors, as a member of the Audit Committee, and as the Senior Director of International Markets.

Prior to joining MedMira, Markus worked with a number of financial institutions in Switzerland, England, and Hong Kong. He holds a BSc from Royal Holloway University of London and has studied business management, strategic planning, investment and accounting at business school in Zurich. Previously, Markus worked in the medical device industry in Africa, Asia Pacific, and Europe.

He will combine his financial expertise with his broad range of international business knowledge to build financial and corporate strategies supporting MedMira’s continuing growth and increasing shareholder value.

Director of the Audit Committee, Nomination and Compensation Committee

Jianhe Mao

Jianhe Mao is the owner of Unipec, a consulting firm based in St. Gallen, Switzerland. Unipec focuses on helping European companies enter the Chinese market, through operational restructuring and ownership and management optimization.

In addition to leading Unipec, Mr. Mao is involved in several industrial projects and start-up ventures including Monsatec AG, a new company bridging the gap between laboratories and clinics with a cold plasma medical device. He serves on the boards of several European companies and is regarded as a trusted expert in legal cases, corporate corruption, operational turnarounds, and mergers and acquisitions.

Mr. Mao began his career as a project engineer and has gained experience in business development and real estate investment. He holds M.E. from Ruhr University Bochum.

CEO, Co-Founder & Co-Inventor

Hermes Chan, D.Sc. (h.c.)

Hermes Chan, our Chief Executive Officer and Co-Founder, leads our passionate and committed team in driving the strategic direction and growth of MedMira.

Hermes, who was named BioScience Innovator of the Year by The Economist in 2007, is the inventor of our patented rapid flow-through diagnostic technology platform.

Since the company’s inception in 1994 Hermes has held progressively senior management roles including Research Scientist, General Manager, Senior Vice President, and Chief Operating Officer.

Prior to creating MedMira, Hermes worked with another Canadian biotechnology company in the diagnostics research sector.

Chair member of the Audit Committee, Nomination and Compensation Committee

Steven Cummings

Mr. Steven Cummings is the Founder & President of Cambridge Financial Services, one of the leading full service accounting, tax, and business advisory firms in Nova Scotia.

Under Mr. Cummings leadership, Cambridge Financial has earned an enviable reputation among businesses and industry for a commitment to high standards. Along with his leadership responsibilities at Cambridge Financial Services, Mr. Cummings was engaged as MedMira’s interim Chief Financial Officer in 2007.

With more than 30 years of financial and entrepreneurial experience, Mr. Cummings is a frequent guest speaker on issues surrounding provincial taxation, taxation of seniors, and business ownership

Intellectual property

China

ZL02819646.5

Rapid Diagnostic Device and Assay

Intellectual property

European union

EP1417489

Rapid Diagnostic Device and Assay

EP1328811

HCV Mosaic Antigen Composition (2021)

Intellectual property

USA

9,164,087

Rapid Diagnostic Device, assay and multifunctional Buffer

9,086,410

Downward or vertical flow diagnostic device and assay

8,025,850

Rapid Diagnostic Device, Assay and Multifunctional Buffer

8,287,817

Rapid Diagnostic Device, Assay and Multifunctional Buffer

8,586,375

Rapid Diagnostic Device, Assay and Multifunctional Buffer

7,531,362

Rapid Diagnostic Device, Assay and Multifunctional Buffer

D706945

Diagnostic Device

D706466

Diagnostic Device

11,353,450

Analyte Detection Using Raman Spectroscopy

Intellectual property

Canada

CA2,493,616

Rapid Diagnostic Device, Assay and Multifunctional Buffer

CA2,740,902

Downward or Vertical Flow Diagnostic Device and Assay

CA2,949,634

Analyte Detection Using Raman Spectroscopy

MiROQ Vision

Handheld Device

A future concept built on the same MIROQ technology, designed to deliver lab-grade precision in the palm of your hand.

We envision a future where testing can happen anywhere, anytime – from hospitals and clinics to remote regions or even at home – enabling early disease detection and turning knowledge into real impact. No large equipment or complex infrastructure required.

For: Doctor’s offices, small and mobile clinics

Future application: Home use

Connectivity: Bluetooth, Wifi and USB